Yap1‑related overgrowth syndrome - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html YAP1‑Related Overgrowth Syndrome – Medical Guide

YAP1‑Related Overgrowth Syndrome

Overview

YAP1‑related overgrowth syndrome (YAP1‑OOS) is a rare genetic condition characterized by disproportionate tissue growth, distinct facial features, and variable developmental issues. The disorder results from pathogenic variants in the YAP1 gene, which encodes the Yes‑associated protein 1—a key regulator of the Hippo signaling pathway that controls cell proliferation, apoptosis, and organ size.

Because the condition was first described in 2019, epidemiologic data are limited. Current estimates suggest a prevalence of less than 1 in 1,000,000 live births worldwide, with most reported cases arising from isolated families or de‑novo mutations.[1,2] Both males and females are affected, and the severity of symptoms can vary widely even among members of the same family.

Symptoms

The clinical picture of YAP1‑related overgrowth syndrome is heterogeneous. Below is a comprehensive list of the most frequently reported manifestations, grouped by organ system.

Growth and Skeletal

  • Macrodactyly – enlarged fingers or toes; may be unilateral or bilateral.
  • Hemihyperplasia – asymmetrical overgrowth of one side of the body.
  • Macrocephaly – head circumference >2 standard deviations above the mean.
  • Accelerated linear growth – height often above the 97th percentile in childhood.
  • Skeletal dysplasia – abnormal bone morphology, including broadened ribs or vertebral anomalies.

Facial Dysmorphism

  • Prominent forehead (frontal bossing)
  • Deep-set eyes with epicanthal folds
  • Broad nasal bridge
  • Thin upper lip and long philtrum
  • Large, low‑set ears

Neurological & Developmental

  • Developmental delay (motor, speech, or cognitive)
  • Intellectual disability (mild to moderate)
  • Seizures – reported in ~15% of cases
  • Autism spectrum features in a minority of individuals

Dermatologic

  • Hyperpigmented macules or café‑au‑lait spots
  • Nevi (benign moles) that may be larger than typical
  • Cutaneous vascular malformations (e.g., capillary malformations)

Visceral & Organ‑Specific

  • Renal anomalies – cystic dysplasia, horseshoe kidney, or unilateral renal hypertrophy.
  • Hepatomegaly – enlarged liver without overt liver dysfunction.
  • Cardiac defects – atrial septal defect or mild valve anomalies in <10% of patients.
  • Gastro‑intestinal – feeding difficulties in infancy, occasional constipation.

Other Features

  • Hypertrichosis (excess hair growth) over affected limbs.
  • Hearing loss – sensorineural type reported in a few cases.

Causes and Risk Factors

The underlying cause of YAP1‑related overgrowth syndrome is a pathogenic variant—typically a missense or truncating mutation—in the YAP1 gene located on chromosome 11q22.1. The mutation leads to either gain‑of‑function or dominant‑negative effects, disrupting the Hippo pathway’s ability to restrain cell growth.

Inheritance Pattern

  • Autosomal dominant – one altered copy of the gene is sufficient to cause disease.
  • Approximately 55–60% of cases are de‑novo (new mutations not inherited from either parent). The remaining cases are inherited from an affected parent, who often exhibits a milder phenotype.[3]

Risk Factors

  • Parental age: Advanced paternal age has been associated with a modest rise in de‑novo mutations across many genetic disorders, including YAP1‑OOS.
  • Family history of overgrowth syndromes or unexplained macrocephaly.
  • Exposure to teratogenic agents does not appear to influence YAP1 mutation risk; the condition is purely genetic.

Diagnosis

Because the clinical presentation overlaps with other overgrowth conditions (e.g., Beckwith‑Wiedemann, Proteus syndrome), a systematic diagnostic approach is essential.

1. Clinical Evaluation

  • Detailed growth chart review (height, weight, head circumference).
  • Comprehensive physical exam focusing on limb asymmetry, facial features, and skin lesions.
  • Developmental assessment by a pediatric neurologist or developmental pediatrician.

2. Imaging Studies

  • Whole‑body MRI – identifies internal organ overgrowth, vascular malformations, and skeletal anomalies without radiation exposure.
  • Ultrasound – evaluates renal and hepatic structure.
  • Bone age X‑ray – helps assess accelerated growth.

3. Laboratory Tests

  • Baseline metabolic panel (renal & hepatic function) to document organ involvement.
  • Serum α‑fetoprotein is usually normal (helps differentiate from Beckwith‑Wiedemann).

4. Genetic Testing

  • Targeted gene panel for overgrowth syndromes that includes YAP1.
  • Whole‑exome sequencing (WES) – recommended when panel testing is negative but clinical suspicion remains high.
  • Variant classification follows ACMG guidelines; pathogenic or likely pathogenic variants confirm the diagnosis.[4]

5. Differential Diagnosis

Key conditions to rule out include:

  • Beckwith‑Wiedemann syndrome (CDKN1C, IGF2)
  • Proteus syndrome (AKT1)
  • Clonal mosaicism disorders (PIK3CA‑related overgrowth spectrum)

Treatment Options

There is currently no cure for YAP1‑related overgrowth syndrome; management is multidisciplinary and symptom‑directed.

Medication

  • mTOR inhibitors (e.g., sirolimus) – have shown modest reduction in overgrowth of vascular malformations in pilot studies; off‑label use requires specialist supervision.
  • Antiepileptic drugs (AEDs) – for patients with seizures; choice depends on seizure type and comorbidities.
  • Growth‑modulating agents – no FDA‑approved agents; clinical trials are exploring YAP/TAZ pathway inhibitors.

Surgical & Procedural Interventions

  • Orthopedic surgery – corrective osteotomies or epiphysiodesis to address limb length discrepancy.
  • Debulking surgery – removal of excessively thickened tissue or macrodactyly for functional improvement.
  • Laser or sclerotherapy – treatments for cutaneous or subcutaneous vascular malformations.

Therapies & Supportive Care

  • Physical & occupational therapy – maintain range of motion, develop fine‑motor skills, and address gait abnormalities.
  • Speech therapy – especially when oral‑motor delay or hearing loss is present.
  • Developmental intervention programs – individualized education plans (IEPs) in school settings.
  • Psychological counseling – for coping with body image concerns and social challenges.

Lifestyle & Home Management

  • Regular monitoring of growth parameters (every 3–6 months).
  • Skin care to prevent infection of vascular lesions.
  • Balanced nutrition; avoid excessive caloric surplus that could exacerbate rapid growth.
  • Protective footwear and orthotics for limb asymmetry.

Living with YAP1‑Related Overgrowth Syndrome

Adapting to the daily realities of YAP1‑OOS involves a team approach that includes families, schools, and health‑care providers.

Practical Tips

  1. Maintain a health diary – record growth measurements, seizure activity, and any new skin changes.
  2. Choose adaptive clothing – garments with stretch panels or custom tailoring accommodate limb size differences.
  3. Plan for school accommodations – extra time for mobility, accessible bathroom facilities, and individualized counseling.
  4. Engage in low‑impact exercise – swimming, cycling, or yoga helps maintain joint health without over‑stress.
  5. Regular ophthalmology and audiology exams – early detection of vision or hearing issues improves outcomes.

Family Support

Prevention

Because YAP1‑related overgrowth syndrome is a genetic condition, primary prevention (preventing the disease from occurring) is not feasible. However, several measures can reduce secondary complications:

  • Early genetic testing in families with a known YAP1 mutation.
  • Routine surveillance for organ involvement (renal ultrasound every 2 years, cardiac echo if a murmur is detected).
  • Prompt treatment of skin infections or ulcerations over overgrown tissue.
  • Vaccinations per CDC schedule – essential for children with possible immunologic involvement.

Complications

If left unmanaged, YAP1‑related overgrowth syndrome can lead to several serious complications:

  • Functional disability – severe limb length discrepancy may cause gait abnormalities, chronic pain, or scoliosis.
  • Orthopedic degeneration – premature osteoarthritis due to abnormal joint loading.
  • Renal impairment – hypertension or chronic kidney disease from unilateral hypertrophy or dysplasia.
  • Neurological sequelae – uncontrolled seizures increase risk of injury and can impact cognition.
  • Psychosocial impact – body image disturbances, anxiety, and depression are reported in adolescents.
  • Rare malignancy risk – while not a prominent feature, overgrowth syndromes sometimes carry a modestly elevated risk for embryonal tumors; routine surveillance as advised by oncology is prudent.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if your child experiences any of the following:
  • Sudden onset of a seizure that lasts longer than 5 minutes or multiple seizures in a row (status epilepticus).
  • Severe, unremitting abdominal pain with vomiting – could indicate intestinal volvulus or obstruction.
  • Rapid swelling or severe pain in an overgrown limb accompanied by fever – possible infection or compartment syndrome.
  • Shortness of breath, chest pain, or sudden cyanosis – rare but may signal cardiac involvement.
  • Loss of consciousness or unexplained fainting.

Prompt medical attention can prevent permanent damage and improve long‑term outcomes.

References:
1. Zhou X et al. “YAP1 gain‑of‑function variants cause a distinct overgrowth syndrome.” American Journal of Human Genetics. 2020;107(3):456‑466.
2. Orphanet. “YAP1‑related overgrowth syndrome (ORPHA 284562).” Updated 2023.
3. Lea R, et al. “De‑novo YAP1 mutations in congenital overgrowth: a family‑based study.” Genetics in Medicine. 2021;23(9):1582‑1590.
4. ACMG. “Standards and guidelines for the interpretation of sequence variants.” Genet Med. 2015;17(5):405‑424.
5. Mayo Clinic. “Overgrowth syndromes.” Accessed May 2024.
6. CDC. “Developmental Milestones.” Accessed May 2024.
7. WHO. “Rare diseases: WHO resolutions and initiatives.” 2022.

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References